Simplify Logo

Full-Time

Manager – Total Rewards

Posted on 6/27/2024

Ceribell

Ceribell

201-500 employees

EEG devices for monitoring brain activity

Hardware
Biotechnology
Healthcare

Compensation Overview

$130k - $150kAnnually

+ Bonus + Equity

Senior, Expert

Sunnyvale, CA, USA

Category
Human Resources
People & HR
Required Skills
Sales
Communications
Requirements
  • Bachelor's degree in HR, Business Administration, Finance, or related field; advanced degree or relevant certifications (e.g., CCP, CBP, CEBS) preferred.
  • Minimum 5 years' experience in total rewards, preferably in Medical Devices, Healthcare, or Life Sciences.
  • Proven experience in developing and administering Sales compensation and commission plans.
  • Proven experience and knowledge designing and implementing competitive compensation structures and benefits packages, as well as in-depth knowledge of compensation and benefits principles, practices, and regulations.
  • Ability to handle complex issues with a high sense of urgency, employee-centric and service focus, exceptional organizational skills and level of integrity/discretion when handling sensitive and confidential information.
  • Strong analytical, communication, and project management skills.
Responsibilities
  • Develop, communicate and administer competitive compensation and benefits programs aligned with organizational goals and legal requirements.
  • Conduct ongoing market analyses to ensure compensation and benefits remain competitive and equitable.
  • Collaborate with finance, leadership and HR teams to continue to develop and enhance total rewards strategies and programs.
  • Lead compensation planning processes, including budgeting and incentive programs.
  • Maintain job classification and leveling processes to ensure fair and consistent compensation in line with the company’s strategic priorities.

Ceribell focuses on developing medical devices that utilize electroencephalogram (EEG) technology to monitor brain activity. Their main product, the Ceribell EEG Headband and Recorder, is designed for use by trained healthcare providers in professional settings. These devices help gather important data about a patient's brain activity, which healthcare professionals can analyze to make informed treatment decisions. Unlike some other EEG devices, Ceribell's products do not provide diagnostic conclusions or automated alerts; instead, they serve as a tool for data collection, particularly in urgent situations like Nonconvulsive Status Epilepticus (NCSE), where timely intervention is crucial. Ceribell differentiates itself by focusing on the speed and efficiency of data gathering, which is vital in critical care scenarios. The company's goal is to enhance the ability of healthcare providers to monitor and respond to neurological conditions effectively.

Company Stage

Series C

Total Funding

$172M

Headquarters

Mountain View, California

Founded

2014

Growth & Insights
Headcount

6 month growth

8%

1 year growth

23%

2 year growth

76%
Simplify Jobs

Simplify's Take

What believers are saying

  • Ceribell's recent $102 million equity investment and $50 million financing round indicate strong financial backing for expansion and product development.
  • The appointment of experienced leaders like Sean Manni and Joshua Copp positions the company for strategic growth and operational excellence.
  • Recognition by Fast Company as one of the World's Most Innovative Companies highlights Ceribell's industry impact and potential for continued innovation.

What critics are saying

  • The reliance on healthcare providers to interpret EEG data may limit the device's adoption in settings with less specialized staff.
  • The competitive landscape in medical devices and AI-powered diagnostics could pose challenges to Ceribell's market share.

What makes Ceribell unique

  • Ceribell's AI-powered point-of-care EEG system is a first-of-its-kind technology, setting it apart from traditional EEG devices.
  • The company's focus on rapid, easy-to-use brain monitoring solutions for time-critical conditions like NCSE provides a unique value proposition.
  • FDA Breakthrough Device Designation for delirium detection further validates Ceribell's innovative approach in neurodiagnostics.
INACTIVE